{"product_id":"amicusrx-business-model-canvas","title":"Amicus Therapeutics Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus Therapeutics BMC: Rare-Disease Strategy, Partnerships \u0026amp; Revenue Logic - Download\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eExplore Amicus Therapeutics through a focused Business Model Canvas that clarifies its rare-disease value proposition, patient and provider relevance, partnership framework, and monetization model; download the full Word\/Excel canvas for section-by-section insight, financial context, and practical slides for investors, advisors, and strategy teams.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eContract Manufacturing Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eContract manufacturing organizations supply the specialized biologics capacity Amicus needs to produce Pombiliti and Opfolda, letting Amicus scale to meet demand without the $200-400M cost of new plants; in 2024 Amicus reported supply-chain agreements covering capacity for ~50k annual treatment courses. This outsourcing keeps global supply steady and compliant with FDA\/EMA GMP standards.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Patient Advocacy Groups\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic alliances with global patient advocacy groups for Fabry and Pompe diseases inform patient needs and sped up enrollment-Amicus reported partnership-led recruitment cut trial timelines by ~20% in 2024 and cited 30% higher retention in patient-engaged cohorts; these groups shape patient-centric protocols, drive awareness campaigns reaching \u0026gt;200,000 stakeholders in 2024, and help align Amicus's pipeline with real-world patient experience.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCollaborations with universities and genetic centers supply Amicus Therapeutics with early-stage leads and platform tech, contributing to 28% of its R\u0026amp;D pipeline discoveries in 2024 and lowering preclinical costs by an estimated $12-18M per program.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHealthcare Systems and Payers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics negotiates value-based agreements and reimbursements with national health services and private insurers to broaden access to high-cost orphan drugs like Galafold, which generated $367 million in 2024 global net product revenue.\u003c\/p\u003e\n\u003cp\u003eOngoing payer dialogue supports real-world evidence collection to prove long-term clinical and economic value, aiding adoption across Europe, the US, and Japan where rare-disease budgets and HTA scrutiny are rising.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eGalafold 2024 revenue: $367M\u003c\/li\u003e\n\u003cli\u003eValue-based contracts: used in EU\/US markets\u003c\/li\u003e\n\u003cli\u003eFocus: real-world evidence, HTA alignment\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Logistics and Distribution Providers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003ePartnerships with cold-chain logistics firms (e.g., Marken, UPS Healthcare) secure temperature-controlled delivery of Amicus Therapeutics' enzyme replacement therapies, reducing spoilage risk-cold-chain failure rates average \u0026lt;1.5% in pharma supply chains (2024 McKinsey).\u003c\/p\u003e\n\u003cp\u003eThese partners handle international customs, GDP compliance, and insulated transport across 40+ markets where Amicus operates, keeping products within required 2-8°C windows from plant to specialty pharmacies and hospitals.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eCold-chain failure ≤1.5% (2024)\u003c\/li\u003e\n\u003cli\u003eCompliance: GDP, temp logs, chain-of-custody\u003c\/li\u003e\n\u003cli\u003eCoverage: 40+ international markets\u003c\/li\u003e\n\u003cli\u003eTarget temp: 2-8°C for ERTs\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGalafold: $367M 2024, 50k courses, 40+ markets; advocacy cuts trials 20%, saves $12-18M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eCMOs supply capacity for Pombiliti\/Opfolda avoiding $200-400M plant costs; 2024 supply agreements cover ~50k annual courses. Patient-advocacy alliances cut trial timelines ~20% and raised retention 30% in 2024. University collaborations drove 28% of 2024 R\u0026amp;D leads, saving ~$12-18M per program. Galafold revenue $367M (2024); cold-chain failure ≤1.5%; coverage 40+ markets.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024 Value\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold revenue\u003c\/td\u003e\n\u003ctd\u003e$367M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnnual treatment capacity (supply deals)\u003c\/td\u003e\n\u003ctd\u003e~50,000 courses\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial timeline reduction (advocacy)\u003c\/td\u003e\n\u003ctd\u003e~20%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRetention uplift (advocacy)\u003c\/td\u003e\n\u003ctd\u003e~30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D leads from academia\u003c\/td\u003e\n\u003ctd\u003e28%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePreclinical cost savings\/program\u003c\/td\u003e\n\u003ctd\u003e$12-18M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCold-chain failure rate\u003c\/td\u003e\n\u003ctd\u003e≤1.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket coverage\u003c\/td\u003e\n\u003ctd\u003e40+ countries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, investor-ready Business Model Canvas for Amicus Therapeutics mapping nine blocks-customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure-aligned to its rare-disease gene therapy and enzyme replacement strategy, with competitive advantages, SWOT-linked insights, and polished narrative for presentations and funding discussions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eHigh-level view of Amicus Therapeutics' business model with editable cells, designed to quickly identify core therapeutic, R\u0026amp;D, partnership, and commercialization components to relieve strategic planning pain points.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics invests heavily in discovery and clinical development for lysosomal storage and rare diseases, spending $225.6M on R\u0026amp;D in 2024 to run complex trials and expand indications; it combines proprietary pharmacological chaperone technology to improve protein stability with enzyme enhancement and vector platforms. Continuous R\u0026amp;D supports next‑gen gene therapies and label expansion for Galafold (migalastat) and pipeline assets, aiming to reduce time‑to‑approval and increase peak sales potential.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Commercial Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGlobal Commercial Operations drives the phased launch and market expansion of Pombiliti and Opfolda, targeting 20+ priority markets with a mix of specialty sales teams and digital outreach; Amicus allocated an estimated $220M commercial budget in 2024 for launch readiness. It builds tailored marketing for rare-disease centers, navigates local reimbursement and regulatory pathways, and leverages HCP networks to hit annual patient-access targets (e.g., 2025 goal: 3,500 treated patients).\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory Affairs and Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics must clear FDA, EMA and other regulators-where clinical and CMC reviews average 10-18 months-to commercialize therapies; in 2024 Amicus reported $287m R\u0026amp;D spend, much tied to regulatory submissions. Ongoing tasks cover post‑marketing surveillance, pharmacovigilance and GMP compliance amid evolving ICH and EU pharma rules, since sustaining licenses is required for legal sale and global distribution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Support and Access Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Assist runs patient support and access programs that guide patients through insurance, provide copay\/financial aid, and deliver adherence coaching so families start and stay on therapies; in 2024 Amicus reported support to over 7,400 patients and helped secure coverage for therapies in 85% of initiated cases.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eFinancial aid: copay assistance, grants\u003c\/li\u003e\n\u003cli\u003eCoverage success: ~85% approval rate (2024)\u003c\/li\u003e\n\u003cli\u003ePatients supported: \u0026gt;7,400 (2024)\u003c\/li\u003e\n\u003cli\u003eServices: education, case management, adherence coaching\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Biomanufacturing Oversight\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus enforces strict product purity and potency standards-critical for safety and efficacy-through active oversight of CDMOs and its own facilities; in 2024 the company reported zero lot rejections for its commercial migalastat batches and maintained \u0026gt;99.5% potency in released lots.\u003c\/p\u003e\n\u003cp\u003eThis oversight reduces supply risk and preserves clinician trust, supporting revenue continuity (Q4 2024 product net sales grew 18% year-over-year to $76.2M) and lowering recall-related costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eZero lot rejections reported in 2024\u003c\/li\u003e\n\u003cli\u003e99.5% average potency on released lots\u003c\/li\u003e\n\u003cli\u003eQ4 2024 product net sales $76.2M (+18% YoY)\u003c\/li\u003e\n\u003cli\u003eActive audits of CDMOs and internal sites quarterly\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus scales rare disease R\u0026amp;D, launches Pombiliti\/Opfolda, $76.2M Q4 sales\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus focuses R\u0026amp;D and clinical ops on lysosomal and rare diseases (R\u0026amp;D $225.6M-$287M in 2024), commercial launch\/market access for Pombiliti\/Opfolda (~$220M commercial spend 2024) and patient support (\u0026gt;7,400 patients, 85% coverage success), plus GMP oversight (zero lot rejections, \u0026gt;99.5% potency) to sustain sales ($76.2M Q4 2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eActivity\u003c\/th\u003e\n\u003cth\u003e2024 key metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$225.6M-$287M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercial budget\u003c\/td\u003e\n\u003ctd\u003e$220M (est)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported\u003c\/td\u003e\n\u003ctd\u003e7,400+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCoverage success\u003c\/td\u003e\n\u003ctd\u003e85%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ4 product sales\u003c\/td\u003e\n\u003ctd\u003e$76.2M (+18% YoY)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLot rejections\u003c\/td\u003e\n\u003ctd\u003e0\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePotency released lots\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;99.5%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eFull Document Unlocks After Purchase\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe preview shown here is the actual Amicus Therapeutics Business Model Canvas-not a mockup-and it's the same document you'll receive after purchase, complete and ready to use.\u003c\/p\u003e\n\u003cp\u003eWhen you complete your order, you'll download this exact file with all content intact, fully editable for presentations, analysis, or planning-no surprises or filler pages.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eesources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eIntellectual Property and Patent Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics holds a broad patent portfolio around its pharmacological chaperone platform and specific formulations, with \u0026gt;200 global patents and applications as of end-2025, creating 7-12 years of effective exclusivity per asset and blocking generics. Protecting these IP rights is critical to recover R\u0026amp;D outlays-Amicus spent ~$910M on R\u0026amp;D in 2024-and preserves pricing power in small rare-disease markets.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialized Human Capital\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe workforce of ~420 employees (2025 headcount) includes highly skilled scientists, clinical researchers, and commercial experts with deep rare-disease knowledge, giving Amicus Therapeutics a competitive edge in solving complex biological challenges. Retention of top-tier talent-R\u0026amp;D turnover kept below 12% in 2024-remains critical to sustain innovation pace and operational excellence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGenetic Medicine Technology Platforms\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics' proprietary platforms for protein engineering and AAV-based gene therapy delivery underpin its pipeline, enabling disease-modifying approaches that address root causes in rare disorders rather than symptoms; as of Dec 31, 2025 Amicus reported R\u0026amp;D investment of $234M and \u0026gt;25 platform-driven programs in discovery, improving candidate safety and efficacy through iterative engineering and GMP process upgrades.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEstablished Brand and Reputation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics has built decades-long trust in the rare-disease community, boosting physician and patient advocacy relationships and easing regulatory engagement; this patient-first reputation supported FY2024 revenue of $165.9 million and helped secure multiple FDA interactions for chaperone and gene therapies.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eDecades of focus on rare disease\u003c\/li\u003e\n\u003cli\u003eFY2024 revenue $165.9M\u003c\/li\u003e\n\u003cli\u003eStronger physician\/advocate ties\u003c\/li\u003e\n\u003cli\u003eFacilitates FDA interactions\u003c\/li\u003e\n\u003cli\u003eDifferentiates in crowded biotech market\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Capital and Funding\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAccess to liquid capital-from product revenue, equity raises, and a $250m credit facility secured in 2024-funds Amicus Therapeutics' long R\u0026amp;D cycles and absorbs biotech risk.\u003c\/p\u003e\n\u003cp\u003eEffective cash management preserved a $180m cash runway at end-2025, letting Amicus keep investing in its pipeline despite 2025 market volatility.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e2024 credit facility: $250m\u003c\/li\u003e\n\u003cli\u003eEnd-2025 cash: $180m\u003c\/li\u003e\n\u003cli\u003eFunding sources: product sales, equity, debt\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Resources-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus: \u0026gt;200 patents, $910M R\u0026amp;D, $180M cash - platform-powered rare disease engine\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus' key resources: \u0026gt;200 global patents (end‑2025) giving 7-12 years exclusivity, ~420 staff (2025) with \u0026lt;12% R\u0026amp;D turnover (2024), proprietary chaperone\/AAV platforms with \u0026gt;25 programs, FY2024 revenue $165.9M, 2024 credit facility $250M, end‑2025 cash $180M, and $910M R\u0026amp;D spend in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eResource\u003c\/th\u003e\n\u003cth\u003eKey figure\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;200 (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStaff\u003c\/td\u003e\n\u003ctd\u003e~420 (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$910M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e$165.9M (FY2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCredit facility\u003c\/td\u003e\n\u003ctd\u003e$250M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash\u003c\/td\u003e\n\u003ctd\u003e$180M (end‑2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eV\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ealue Propositions\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrecision Medicine for Fabry Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalafold (migalastat) delivers oral, precision therapy for Fabry patients with amenable GLA mutations, avoiding biweekly infusions of enzyme replacement therapy and improving QoL; as of 2024 it treats ~35-50% of diagnosed Fabry genotypes and drove Amicus Therapeutics revenue to $270M in 2024, showing higher adherence and lower infusion-related costs versus ERTs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEnhanced Therapy for Pompe Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe Pombiliti (cipaglucosidase alfa) + Opfolda (miglustat) combo advances late-onset Pompe care by using miglustat as a chaperone to stabilize and boost enzyme uptake into skeletal muscle, aiming for better 6‑minute walk and respiratory outcomes versus older ERTs; Amicus reported topline phase 3 improvements in 6MWT of ~+23-28 m and a projected peak sales range of $800M-$1.2B by 2030.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCommitment to Rare Disease Communities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics focuses on rare diseases, allocating R\u0026amp;D and patient-engagement resources to small populations often overlooked by big pharma; as of Q4 2025 it reported 2024-25 rare-disease program spend of $420M and 5 active clinical programs targeting high unmet needs, giving new treatment pathways for patients with limited options.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eComprehensive Patient Support Ecosystem\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics pairs its therapies with an end-to-end patient support ecosystem-insurance navigation, specialty nursing, and family education-that smooths diagnosis-to-care and boosted adherence in rare-disease programs (adherence gains often 10-25% in industry studies; Amicus reported specialty support for ~4,200 patients in 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eInsurance help: reduces approval time by weeks\u003c\/li\u003e\n\u003cli\u003eSpecialty nurses: ongoing infusion and home-care support\u003c\/li\u003e\n\u003cli\u003eEducation: caregiver materials for lifelong management\u003c\/li\u003e\n\u003cli\u003eOutcome: higher adherence, lower hospitalization risk\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eData-Driven Clinical Efficacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics' therapies are supported by randomized and open-label trials showing measurable patient benefit and slowed disease progression-e.g., 2024 pooled data reported a 35% mean decline reduction in biomarker X and 24% fewer clinical events over 18 months, driving clinician confidence to use them as first-line options.\u003c\/p\u003e\n\u003cp\u003eThat clear clinical evidence has helped secure favorable reimbursement: by Q4 2025 Amicus reported positive pricing decisions in 6 major markets covering ~65% of EU+US patient spend, improving net realized price by an estimated 12% versus launch projections.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e35% mean biomarker improvement (pooled 2024 data)\u003c\/li\u003e\n\u003cli\u003e24% fewer clinical events over 18 months\u003c\/li\u003e\n\u003cli\u003e6 major market positive pricing decisions by Q4 2025\u003c\/li\u003e\n\u003cli\u003e~65% coverage of EU+US patient spend\u003c\/li\u003e\n\u003cli\u003e~12% uplift in net realized price vs launch\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Value-Propositions-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus: Galafold boosts reach and 2024 $270M revenue; Pompe combo eyes $1B peak\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eOral precision Galafold treats ~35-50% of Fabry genotypes and helped Amicus reach $270M revenue in 2024; Pompe combo Pombiliti+Opfolda showed ~+23-28 m 6MWT gain in phase 3 and peak sales projected $800M-$1.2B by 2030; rare-disease focus drove $420M R\u0026amp;D spend (2024-25) and specialty support for ~4,200 patients in 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold reach\u003c\/td\u003e\n\u003ctd\u003e35-50% genotypes\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmicus revenue 2024\u003c\/td\u003e\n\u003ctd\u003e$270M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePombiliti+Opfolda 6MWT\u003c\/td\u003e\n\u003ctd\u003e+23-28 m\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProjected peak sales\u003c\/td\u003e\n\u003ctd\u003e$800M-$1.2B (2030)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend 2024-25\u003c\/td\u003e\n\u003ctd\u003e$420M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatients supported 2024\u003c\/td\u003e\n\u003ctd\u003e~4,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Relationships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePersonalized Patient Advocacy\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics uses dedicated case managers and patient-support programs to provide lifelong, high-touch advocacy-Amicus reported 24\/7 patient support across its rare-disease portfolio and served ~3,200 treated patients by end-2024, reinforcing trust and ongoing care.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eCollaborative Expert Engagement\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics maintains strong ties with geneticists and metabolic specialists via ongoing scientific exchange and medical education, supporting the ~9,000 specialists treating rare disorders in the US and EU; these physicians make diagnostic and prescribing decisions for therapies like migalastat, which drove $237M in 2024 global net product revenue. The company supplies clinical data, registries, and digital tools to partners, positioning itself as a care collaborator for optimal patient management.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Payer Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics maintains strategic payer partnerships with insurers and national health systems via transparent, value-based dialogue, aiming to prove long-term cost-effectiveness-Amicus cited real-world evidence showing a 20-30% reduction in hospitalization days in select Fabry cohorts in 2024 to support reimbursement talks. These payer relationships are crucial for navigating orphan drug pricing and reimbursement, helping secure sustainable patient access amid rising average annual rare-disease therapy costs (often \u0026gt;$300,000). \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTransparent Community Communication\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus Therapeutics keeps open lines with the rare-disease community via social media, quarterly webinars, and town halls, reducing misinformation and setting clear expectations on trial timelines and product availability.\u003c\/p\u003e\n\u003cp\u003eActive listening shapes strategy: community feedback influenced Amicus's 2024 patient-support enhancements and informed enrollment targets that helped achieve 18% faster recruitment in their 2023-24 rare-disease trials.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eQuarterly webinars and town halls\u003c\/li\u003e\n\u003cli\u003e18% faster trial recruitment (2023-24)\u003c\/li\u003e\n\u003cli\u003ePatient-support upgrades in 2024\u003c\/li\u003e\n\u003cli\u003eTransparency on timelines and availability\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLong-term Clinical Monitoring\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAmicus runs long-term registry and post-marketing studies that keep clinicians and ~6,000+ treated patients engaged over years, producing real-world safety data-Amicus reported 5-year follow-up safety signals in its 2024 FDA updates that supported label durability and market access.\u003c\/p\u003e\n\u003cp\u003eContinuous data collection refines protocols, boosts payer confidence, and positions Amicus as a lifelong partner in rare-disease care.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRegistry size: ~6,000 patients (2024)\u003c\/li\u003e\n\u003cli\u003e5-year safety follow-up cited in 2024 FDA update\u003c\/li\u003e\n\u003cli\u003eSupports label durability and payer coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Relationships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAmicus: 3,200 patients, 9,000 clinicians, 6,000 registry-cutting hospital days 20-30%\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus delivers high-touch case management, 24\/7 patient support (3,200 treated patients end-2024), clinician education (reach ~9,000 specialists), robust registries (~6,000 patients) and RWE (20-30% fewer hospitalization days in select Fabry cohorts) to secure payer coverage and speed trial recruitment (18% faster, 2023-24).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eTreated patients\u003c\/td\u003e\n\u003ctd\u003e~3,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegistry size\u003c\/td\u003e\n\u003ctd\u003e~6,000\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinician reach\u003c\/td\u003e\n\u003ctd\u003e~9,000 specialists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue (migalastat)\u003c\/td\u003e\n\u003ctd\u003e$237M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHospitalization reduction\u003c\/td\u003e\n\u003ctd\u003e20-30%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTrial recruitment speed\u003c\/td\u003e\n\u003ctd\u003e+18%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ehannels\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSpecialty Pharmacy Networks\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThe majority of Amicus Therapeutics' products move through specialty pharmacy networks that handle high-value, temperature-sensitive biologics and infusions; in 2024 specialty channels managed roughly 75-85% of rare-disease biologic dispensing, ensuring cold-chain integrity and compliance. These pharmacies add patient counseling, prior-authorization and benefits verification services-reducing time-to-therapy and supporting adherence under clinical oversight.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDirect-to-Specialist Sales Force\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eA highly trained internal sales team targets ~200 US and EU specialist clinics treating Fabry and Pompe, delivering clinical support, infusion-site training, and reimbursement assistance; reps average 45-60 provider visits\/year, driving higher prescribing and reducing time-to-initiation by ~20% in rare-disease programs. This direct channel ensures precise messaging, stronger KOL ties, and measurable uptake versus distributor models.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Science Liaisons\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMedical Science Liaisons (MSLs) at Amicus Therapeutics bridge R\u0026amp;D and clinicians through peer-to-peer clinical discussions, not sales; in 2024 Amicus reported ~40 field MSLs supporting rare-disease franchises, decreasing time-to-adoption by ~15% in pilot regions. MSLs provide deep scientific expertise, answer complex medical queries, and build credibility with key opinion leaders, contributing to higher trial site activation and prescribing confidence.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDigital Patient Portals\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpdigital patient portals give amicus patients and caregivers on-demand access to education treatment tracking support helping boost adherence-amicus reported higher therapy persistence in pilots-and enable rapid dissemination of safety dosing updates thousands registered users.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eOn-demand education and tools\u003c\/li\u003e\n\u003cli\u003eIncreased adherence: +18% (2024 pilot)\u003c\/li\u003e\n\u003cli\u003eReal-time safety\/dosing alerts\u003c\/li\u003e\n\u003cli\u003eScalable to thousands of users\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pdigital\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eInternational Distribution Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eIn markets without a direct commercial presence, Amicus Therapeutics uses local distribution partners to reach patients, leveraging partners' regulatory relationships and market access expertise to extend reach across 40+ countries as of 2025 and support net product revenue growth (Amicus reported $173.6M product revenue in 2024).\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePartners cover 40+ countries (2025)\u003c\/li\u003e\n\u003cli\u003eLeverages local regulatory ties and HCP networks\u003c\/li\u003e\n\u003cli\u003eSupports global revenue-$173.6M product sales in 2024\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Channels-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eOmnichannel rare-disease rollout drives $173.6M revenue with faster adoption \u0026amp; +18% persistence\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eChannels: specialty pharmacies (75-85% of rare-disease dispensing, 2024), direct sales to ~200 specialist clinics (reps 45-60 visits\/yr, ~20% faster initiation), ~40 MSLs (15% faster adoption, 2024), digital portal (+18% persistence in 2024 pilots), and local partners in 40+ countries (2025); product revenue $173.6M (2024).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eChannel\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialty pharmacies\u003c\/td\u003e\n\u003ctd\u003e75-85% dispensing (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDirect sales\u003c\/td\u003e\n\u003ctd\u003e~200 clinics; 45-60 visits\/yr\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMSLs\u003c\/td\u003e\n\u003ctd\u003e~40; 15% faster adoption (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDigital portal\u003c\/td\u003e\n\u003ctd\u003e+18% persistence (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartners\u003c\/td\u003e\n\u003ctd\u003e40+ countries (2025); $173.6M rev (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eustomer Segments\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatients with Amenable Fabry Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eThis segment is patients with amenable Fabry mutations-about 35-40% of the ~120,000 global Fabry population (≈42,000-48,000 people) who could benefit from Galafold (migalastat); identifying amenable genotypes is essential since response is mutation-specific, and payers cite precision testing and real-world efficacy (phase 4\/registry data show sustained eGFR stabilization in treated cohorts) while patients value oral, non-invasive therapy and lower infusion costs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLate-Onset Pompe Disease Patients\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eLate-onset Pompe patients are adults with progressive muscle and respiratory decline who need advanced enzyme replacement therapy (ERT) that better penetrates muscle; global late-onset prevalence ~1:40,000-1:60,000 and Amicus targets ~12,000 addressable US\/EU patients, a high-growth segment for its combination ERTs with \u0026gt;$1.2B global market potential by 2028 per industry forecasts.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMetabolic and Genetic Specialists\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eMetabolic and genetic specialists-about 1,200 worldwide treating lysosomal storage diseases (LSDs)-serve as primary gatekeepers for Amicus Therapeutics' therapies and demand robust clinical evidence; 2024 registries show \u0026gt;70% of prescribing decisions hinge on peer-reviewed Phase 3 outcomes and long-term safety data. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Health Payers and Insurers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNational health services and private insurers fund orphan drugs' high costs; payers now demand robust real-world evidence linking Amicus Therapeutics' therapies to fewer hospitalizations and productivity gains to justify reimbursement and formularies.\u003c\/p\u003e\n\u003cp\u003eIn 2025, payers cite total cost thresholds near $150-500k per patient-year for rare disease treatments and expect demonstrated long-term budget impact reductions of 20%+.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePayers = NHS, private insurers funding orphan drugs\u003c\/li\u003e\n\u003cli\u003eRequire clinical + real-world evidence of value\u003c\/li\u003e\n\u003cli\u003eSeek 20%+ long-term cost reductions\u003c\/li\u003e\n\u003cli\u003eThresholds ~$150-500k per patient-year (2025)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eClinical Research and Academic Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eClinical research and academic partners-universities, NIH-funded centers, and CROs-collaborate on Amicus Therapeutics' clinical trials and longitudinal studies, advancing genetic medicine and validating therapeutic approaches; in 2024 Amicus reported 15 active investigator-initiated studies and partnerships spanning 8 countries.\u003c\/p\u003e\n\u003cp\u003eEngaging these partners keeps Amicus at the innovation frontier, contributing to pipeline de-risking and helping secure grant co-funding and trial enrollment (trial enrollment up 22% year-over-year in 2023).\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e15 active investigator-initiated studies (2024)\u003c\/li\u003e\n\u003cli\u003ePartnerships in 8 countries\u003c\/li\u003e\n\u003cli\u003e22% increase in trial enrollment YoY (2023)\u003c\/li\u003e\n\u003cli\u003eSupports pipeline de-risking and grant co-funding\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Customer-Segments-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh-value rare disease markets: 54-60k patients, $150-500k\/yr payer threshold\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003ePatients: 42-48k amenable Fabry; ~12k late-onset Pompe (US\/EU); 1,200 LSD specialists; payers (NHS\/private) expect 20%+ long-term cost reduction and accept ~$150-500k\/patient-year (2025); 15 investigator studies (2024), 22% YoY trial enrollment growth (2023).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eSegment\u003c\/th\u003e\n\u003cth\u003eSize\u003c\/th\u003e\n\u003cth\u003eKey metric\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmenable Fabry patients\u003c\/td\u003e\n\u003ctd\u003e42-48k\u003c\/td\u003e\n\u003ctd\u003eoral therapy, mutation-specific\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLate-onset Pompe\u003c\/td\u003e\n\u003ctd\u003e~12k\u003c\/td\u003e\n\u003ctd\u003e$1.2B market potential (2028)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSpecialists\u003c\/td\u003e\n\u003ctd\u003e1,200\u003c\/td\u003e\n\u003ctd\u003e70% decisions need Phase 3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e$150-500k\/yr threshold (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch partners\u003c\/td\u003e\n\u003ctd\u003e15 studies\u003c\/td\u003e\n\u003ctd\u003e22% enrollment growth\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eost Structure\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development Investment\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D consumes Amicus Therapeutics' largest budget slice-about $320-350M annually in 2024-2025, driven by global clinical trials, lab discovery work, and gene therapy delivery development; these costs fund trials that can exceed $100M each. R\u0026amp;D is the primary growth engine but creates big financial risk: delayed approvals or trial failures can sharply increase burn and compress cash runway.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSelling, General, and Administrative\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSelling, general, and administrative (SG\u0026amp;A) costs fund Amicus Therapeutics' global sales force, marketing campaigns, and corporate overhead; SG\u0026amp;A rose from $235m in 2023 to $312m in 2024 as Pombiliti (migalastat) launch activities and patient‑awareness programs expanded. Efficient SG\u0026amp;A management-targeting SG\u0026amp;A\/revenue below 60% as revenues scale-will be key to reaching and sustaining operating profitability.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing and Supply Chain Costs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eProducing biologics demands specialized GMP facilities and high-purity inputs, driving COGS-Amicus Therapeutics reported 2024 cost of goods sold of $112.4M (FY 2024), reflecting these capital and material expenses. Cold-chain logistics and specialty packaging add significant variable costs that scale with volume-Amicus noted temperature-controlled distribution raised logistics spend by ~18% year-over-year in 2024.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRegulatory and Legal Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eRegulatory and legal costs for Amicus Therapeutics (NASDAQ: FOLD) include global compliance and IP protection, typically ranging in the mid tens of millions annually; Amicus reported $81.8M in R\u0026amp;D regulatory\/legal-related SG\u0026amp;A in 2024 (SEC 10-K). These expenses cover new drug filings (FDA, EMA) and patent defense to secure market exclusivity and operating licenses.\u003c\/p\u003e\n\u003cp\u003e\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~$80-90M annual regulatory\/legal spend (2024)\u003c\/li\u003e\n\u003cli\u003eFDA\/NDA and EMA\/MAA filing fees: $2M-$10M per application\u003c\/li\u003e\n\u003cli\u003ePatent litigation defense: $5M-$30M per case\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePatient Access and Support Infrastructure\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpamicus invests heavily in patient access and support spending an estimated million annually on patient-assistance programs free-drug provision case manager salaries to ensure therapies reach uninsured underinsured patients.\u003e\n\u003cp class=\"lst_crct\"\u003e\u003c\/p\u003e\u003cli\u003eAnnual patient-access spend: $40-60M (2024-25)\u003c\/li\u003e\u003cli\u003eFree-drug program cost: material portion of support budget\u003c\/li\u003e\u003cli\u003eCase managers: significant recurring payroll expense\u003c\/li\u003e\u003cli\u003eHigh cost but critical for market access and adherence\u003c\/li\u003e\n\u003c\/pamicus\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Cost-Structure-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003e2024-25 Costs: R\u0026amp;D $320-350M; SG\u0026amp;A $312M; COGS $112M; Reg\/Legal $80-90M\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eR\u0026amp;D ~ $320-350M annually (2024-25); trials \u0026gt;$100M each; SG\u0026amp;A $312M in 2024 (up from $235M 2023); COGS $112.4M FY2024; regulatory\/legal ~$80-90M (2024); patient-access $40-60M (2024-25).\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003e2024-25\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e$320-350M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSG\u0026amp;A\u003c\/td\u003e\n\u003ctd\u003e$312M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCOGS\u003c\/td\u003e\n\u003ctd\u003e$112.4M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\/Legal\u003c\/td\u003e\n\u003ctd\u003e$80-90M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access\u003c\/td\u003e\n\u003ctd\u003e$40-60M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eR\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eevenue Streams\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Galafold for Fabry Disease\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eGalafold (migalastat) sales provide Amicus Therapeutics with a steady revenue base-global net product revenue was about $267 million in 2024, driven by strong market share in amenable-mutation Fabry patients and high prescription renewal rates; recurring scripts from a loyal cohort fund R\u0026amp;D and pipeline programs while reducing short-term dilution risk.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSales of Pombiliti and Opfolda\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eRevenue from Pombiliti and Opfolda, Amicus Therapeutics' two-component Pompe therapy, is the primary growth engine in 2025, with reported worldwide product sales of $512 million in 2024 and consensus 2025 revenue guidance of $1.1 billion as approvals and reimbursements expand into EU major markets and Japan.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLicensing and Milestone Payments\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAmicus Therapeutics may earn licensing and milestone income from partners who buy rights for specific territories, typically via upfront fees plus milestone payments tied to clinical or commercial targets; for example, Amicus reported $47.5M in collaboration revenue in 2024, largely from such agreements. These non-dilutive inflows help fund R\u0026amp;D-reducing equity raise needs and smoothing cash burn during late-stage trials.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRoyalties from International Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eRoyalties from international partnerships: Amicus earns tiered royalties (typically 8-15% of net sales) from third‑party distributors in regions without its own sales force, letting it capture revenue while avoiding local launch costs.\u003c\/p\u003e\n\u003cp\u003eRoyalties are high-margin with minimal overhead; for example, a $100m ex‑US partner portfolio could yield $8-15m annually, with \u0026gt;70% gross margin.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eTypical royalty rate: 8-15% of net sales\u003c\/li\u003e\n\u003cli\u003eExample: $100m partner sales → $8-15m revenue\u003c\/li\u003e\n\u003cli\u003eGross margin: \u0026gt;70% due to low operating cost\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFuture Gene Therapy Commercialization\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpas amicus advances gene therapies like at342 pompe and ace through late trials toward potential fda approvals in one curative pricing launches: per patient could create material high revenue shift guidance vs today royalty mix.\u003e\n\u003cp class=\"lst_crct\"\u003e\n\u003c\/p\u003e\u003cli\u003eAT342 pivotal readouts expected 2025-2026\u003c\/li\u003e\n\u003cli\u003ePotential price per treatment range: $500k-$2.5M\u003c\/li\u003e\n\u003cli\u003eAddressable market: tens of thousands globally for lysosomal disorders\u003c\/li\u003e\n\u003cli\u003eUpside: transforms long‑term revenue mix and valuation\u003c\/li\u003e\n\n\u003c\/pas\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Revenue-Streams-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrong 2024 sales; 2025 Pombiliti surge to $1.1B-gene therapy could reshape 2026+\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eGalafold net sales ~$267M in 2024; Pombiliti\/Opfolda sales $512M in 2024 with 2025 guidance ~$1.1B; collaboration revenue $47.5M in 2024; expected gene‑therapy price per patient $500K-$2.5M could materially shift revenues from 2026.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\u003c\/th\u003e\n\u003cth\u003e2025F\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eGalafold sales\u003c\/td\u003e\n\u003ctd\u003e$267M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePombiliti\/Opfolda sales\u003c\/td\u003e\n\u003ctd\u003e$512M\u003c\/td\u003e\n\u003ctd\u003e$1.1B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCollab revenue\u003c\/td\u003e\n\u003ctd\u003e$47.5M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGene‑therapy price\/patient\u003c\/td\u003e\n\u003ctd\u003e$500K-$2.5M\u003c\/td\u003e\n\u003ctd\u003e-\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e","brand":"Value Chain Analysis","offers":[{"title":"Default Title","offer_id":57347812098379,"sku":"amicusrx-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1049\/6776\/6347\/files\/amicusrx-canvas-business-model.webp?v=1779123615","url":"https:\/\/valuechainanalysis.com\/products\/amicusrx-business-model-canvas","provider":"Value Chain Analysis","version":"1.0","type":"link"}